Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × tremelimumab × Gastrointestinal × Clear all

Phase

Status

Recruiting 28 Completed 25 Active not recruiting 13 Withdrawn 6 Not yet recruiting 4 Unknown 2 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 5 Genitourinary 4 Head & Neck 2 Dermatologic 2 Plasma cell 1 Other solid neoplasm 1 Other neoplasm 1 Gynecologic 1 Gastrointestinal 1 Endocrine 1

Conditions

Cholangiocarcinoma 1

Interventions

Fluorouracil 136 Oxaliplatin 127 Gemcitabine 122 Capecitabine 118 Leucovorin 101 Irinotecan 92 Bevacizumab 84 Cetuximab 61 Cisplatin 59 pembrolizumab 56 Radiotherapy 53 Nivolumab 38 Sorafenib 37 130-nm albumin-bound paclitaxel 35 Docetaxel 31 Radiosurgery 26 Albumin-Bound Paclitaxel 24 Paclitaxel 23 Surgical Procedures, Operative 22 regorafenib 20 Panitumumab 20 Erlotinib Hydrochloride 20 Cyclophosphamide 20 IFL protocol 16 Celecoxib 16 Carboplatin 16 atezolizumab 15 Trastuzumab 15 Radiation 15 Neoadjuvant Therapy 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04989218 2024-11-05

ICC

University of Alabama at Birmingham

Phase 1/2 Terminated

1 enrolled 11 charts

Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡